Tumefactive Multiple sclerosis
Potjana Jitawatanarat, Bhatraphol Tingpej and Paul Deringer
Cite this article as: BJMP 2011;4(2):a419
Keywords: Multiple sclerosis, Tumefactive multiple sclerosis
Tumefactive multiple sclerosis (MS) is a rare variant of MS. This form of MS can masquerade as neoplasm or infectious etiology. Understanding of the disease is limited to case report but it is associated with high morbidity and mortality.
A 44 year old man presented with a 2-month history of progressive right upper extremity weakness, confusion and visual change. Physical exam revealed weakness, hyperreflexia on the right side and right homonymous hemianopia. MRI of the brain showed multiple ring-enhancing lesions located in both cerebral hemispheres. CSF analysis disclosed elevated protein with positive oligoclonal bands and myelin basic protein. Stains and cultures for bacteria and mycobacteria were negative. Serologies including HIV, Toxoplasmosis, and Lyme were all negative. Patient was treated with high-dose IV corticosteroid and clinically improved. One month later, he presented with increasing confusion, aphasia and progressive weakness. Repeat MRI of the brain revealed worsening multiple ring-enhancing lesions with surrounding vasogenic edema in most lesions. High-dose corticosteroid was promptly started. There was also concern about infection, especially brain abscess; hence, intravenous ceftriaxone, vancomycin, and metronidazole were empirically given. Due to uncertainty of diagnosis, first brain biopsy at right frontal lobe lesion yielded non-specific gliosis. Repeat MRI brain showed increasing number of ring-enhancing lesions in both cerebral hemispheres. As a result, a second brain biopsy was performed, which showed an active demyelinating process consistent with multiple sclerosis. Patient experienced severe disability and was discharged to long-term facility with slowly tapered schedule of corticosteroid. He was readmitted several times and eventually family decided hospice care.
Multiple sclerosis is diagnosed by demonstrating clinical and/or radiographic evidence of dissemination of disease in time and space1. Tumefactive MS is a term used when the clinical presentation and/or MRI findings are indistinguishable from a brain tumor2. Not all case of tumefactive MS are fulminant. Marburg variant MS is an acute rare variant of MS which has a rapidly progressive course with frequent, severe relapses leading to death or severe disability within weeks to months3. The tumefactive demyelinating lesions are defined as large (>2 cm.) white matter lesions with little mass-like effect or vasogenic edema, and post-gadolinium magnetic resonance imaging (MRI) typically showing an incomplete ring enhancement2,4. The clinical and imaging characteristics of these demyelinating lesions may mimic primary and secondary brain tumors, brain abscess, tuberculoma, and other inflammatory disorders e.g. sarcoidosis, primary sjogren’s syndrome5. As a result, tumefactive MS is frequently misdiagnosed. There are some MRI characteristics that are more suggestive of tumefactive demyelinating lesions than of other etiologies. These include incomplete ring enhancement, mixed T2-weighted iso-and hyperintensity of enhanced regions, absence of a mass effect and absence of cortical involvement2,6. Differential diagnosis of rapidly progressive neurological deficit with ring-enhancing lesions include brain abscess, primary brain neoplasm or brain metastasis, acute disseminated encephalomyelitis (ADEM) and tumefactive multiple sclerosis. Careful clinical history, CSF study, serial MRI evaluation and follow-up are usually sufficient to make a diagnosis. Some cases pose considerable diagnostic difficulty owing to clinical and radiographical resemblance to brain tumor, for which biopsy may be warranted. Pathologically, the lesions are characterized by massive macrophage infiltration, acute axonal injury, and necrosis. No specific histological features distinguished specimens derived from patients developing classic multiple sclerosis from those who had tumefactive form7. A limited number of cases of Marburg’s variant MS have been reported in the literature whereby most patients died within a period of weeks to months. Only two cases survived after one year7,8. There is no current standard treatment for this condition. Plasma exchange and Mitoxantrone are reportedly showed some promising options9,10.
Figure A: FLAIR imaging at first presentation showed lesion in both hemisphere. Figure B: FLAIR imaging at one month later showed progression of multiple lesion in both hemisphere. Figure C: T1 Post contrast imaging showed intense ring enhancement pattern in almost all lesions with mild edema and minimal mass effect. Figure D: Showed lesion view as sagittal section.
Our patient presented somewhat like a stroke with visual field defect and right hemiparesis which is unusual in MS, but MRI and CSF exam yielded a diagnosis of probable MS. Because of his abrupt clinical deterioration and impressive worsening of his MRI, concern was raised about possibility of infection or neoplasm. Hence, he received two brain biopsies, the second of which showed active demyelination, confirming the diagnosis of severe tumefactive multiple sclerosis and can be consider as a Marburg variant multiple sclerosis.
Marburg variant multiple sclerosis carries a high morbidity and mortality. This disease notoriously mimics other conditions leading to delay diagnosis and treatment. Absence of definitive diagnosis test apart from brain biopsy makes diagnosis, prognosis and treatment decisions difficult.
POTJANA JITAWATANARAT, MD Internal Medicine Resident, Bassett Medical Center, Cooperstown, NY BHATRAPHOL TINGPEJ, MD Internal Medicine Resident, Bassett Medical Center, Cooperstown, NY PAUL DERINGER, MD Neurology Attending, Bassett Medical Center, Cooperstown, NY
CORRESPONDENCE: POTJANA JITAWATANARAT, MD Internal Medicine resident, Bassett Medical Center, Cooperstown, NY
Email: [email protected]
1. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of multiple sclerosis. Ann Neurol.2001; 50: 121–7.2. Dagher AP, Smirniotopoulos J. Tumefactive demyelinating lesions. Neuroradiology. 1996; 38: 560–5.3. Canellas AR, Gols AR, Izquierdo JR, et al. Idiopathic inflammatory-demyelimating disease of central nervous system. Neuroradiology.2007; 49:393-409.4. Lucchinetti CF, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain.2008; 131:1759-75.5. Sanahuja J, Ordonez-Palau S, Beque R, Brieva L, Boquet D. Primary Sjogren syndrome with tumefactive central nervous system involvement. Am J Neuroradiol.2008 Nov; 29(10):1878-79.6. Kim DS, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: Added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology. 2009; 251:467-75.7. Turatti M, Gajofatto A, Rossi F, et al. Long survival and clinical stability in Marburg variant multiple sclerosis. Neurol Sci. 2010; 31(6):807-11.8. Giubilei F, Sarrantonio A, Teisei P, et al. Four-year follow-up of a case of acute multiple sclerosis of the Marburg type. Ital J Neurol Sci.1997; 18:163-166.9. Jeffery DR, Lefkowitz DS, Crittenden JP. Treatment of Marburg variant multiple sclerosis with mitoxanthrone. J Neuroimaging. 2004; 14:58-6210. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology.1993; 43 (6):1100-4.
The above article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.